{"id":106875,"date":"2025-10-21T16:19:31","date_gmt":"2025-10-21T14:19:31","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/the-fda-has-approved-som-biotechs-phase-3-study-design-for-som3355-a-potential-drug-for-huntington-disease\/"},"modified":"2025-10-22T13:48:51","modified_gmt":"2025-10-22T11:48:51","slug":"the-fda-has-approved-som-biotechs-phase-3-study-design-for-som3355-a-potential-drug-for-huntington-disease","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/the-fda-has-approved-som-biotechs-phase-3-study-design-for-som3355-a-potential-drug-for-huntington-disease\/","title":{"rendered":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease"},"content":{"rendered":"<p><strong>The biotechnology company <a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/som-biotech\/\" target=\"_blank\" rel=\"noopener\">SOM Biotech<\/a>, headquartered at the Barcelona Science Park and dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, has received the endorsement of the U.S. Food and Drug Administration (FDA) to continue the development of its drug SOM3355, intended for the treatment of Huntington\u2019s disease, a rare and progressive neurological disorder. After reviewing the results of Phase 2, the FDA has given the green light to the Phase 3 study design, the step prior to potential drug approval, which will also include an open-label extension (OLE) to evaluate long-term effects.<\/strong><\/p>\n<p>SOM3355 is an innovative drug that acts on the brain in a multimodal way, combining the effect of a selective \u03b2-blocker with the inhibition of VMAT1 and VMAT2, two proteins that act as transporters of neurotransmitters such as dopamine within neurons. This mechanism helps regulate chemical messaging in the brain, contributing to the reduction of involuntary movements and the mood and behavioral changes typical of Huntington\u2019s disease.<\/p>\n<p>The drug has successfully completed an initial proof-of-concept study and a Phase 2b clinical trial, showing promising results that could improve patients\u2019 quality of life and offer new hope for this hereditary neurodegenerative disease, which causes coordination and speech difficulties, anxiety, and depression.<\/p>\n<p>\u201cWe are very pleased with this positive outcome with the FDA, in addition to the recent excellent feedback from the EMA; both agencies have confirmed the potential of SOM3355 for the treatment of Huntington\u2019s disease,\u201d said <strong>Silvia Panigone<\/strong>, CEO of SOM Biotech. \u201cWe appreciate the supportive and constructive discussions with the FDA and the alignment on the Phase 3 study design, which could lead to the approval of the first drug capable of addressing the complex symptomatology of Huntington\u2019s disease, including chorea and behavioral and psychiatric symptoms such as depression and anxiety.\u201d<\/p>\n<p>Currently, authorized drugs only treat chorea, all carry a black box warning for increased risk of depression and suicidal thoughts, and have side effects difficult to distinguish from disease progression.<\/p>\n<p>The results of SOM Biotech\u2019s Phase 2b study in Huntington\u2019s disease were very promising. Participants who received SOM3355 not only experienced a significant improvement in involuntary movements (chorea) but also showed a reduction in anxiety and improvement in depressive symptoms. Additionally, the study confirmed that the drug does not cause drowsiness, a common side effect in other treatments.<\/p>\n<p>\u201cThese results, showing a positive effect on depression and anxiety, without drowsiness and with improvement in chorea, are unprecedented and address the unmet need for an effective and well-tolerated drug to treat Huntington\u2019s disease across its different stages,\u201d explained <strong>Rossella Medori<\/strong>, Chief Medical Officer (CMO) of SOM Biotech. \u201cEfficacy on behavioral and psychiatric symptoms, along with a favorable safety profile, will make SOM3355 the symptomatic treatment of choice for Huntington\u2019s disease,\u201d added <strong>Panigone<\/strong>.<\/p>\n<p>The Phase 3 clinical trial, double-blind and placebo-controlled, which will support drug approval, is scheduled to start in Q4 2026 and will test a single dose of SOM3355. Participants with mild to severe Huntington\u2019s disease will be randomized to receive 600 mg of SOM3355 daily or a placebo for three months (12 weeks). Upon completion of the study, participants will have the option to join a nine-month open-label extension (OLE) to assess the potential positive impact on disease progression.<\/p>\n<p>\u201cWe are fully committed to moving forward with the pivotal trial and continuing discussions with the FDA. The alignment with the Agency on a three-month study gives us a short timeframe for potential approval,\u201d concluded <strong>Medori<\/strong>.<\/p>\n<p><strong>\u00bb Link to the news<\/strong>: <a href=\"https:\/\/sombiotech.com\/som-biotech-secures-clear-registrational-path-for-som3355-in-huntingtons-disease-after-fda-end-of-phase-2-meeting\/\" target=\"_blank\" rel=\"noopener\">SOM Biotech website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The biotechnology company SOM Biotech, headquartered at the Barcelona Science Park and dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, has received the&#8230;<\/p>\n","protected":false},"author":14,"featured_media":106869,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[90],"tags":[359],"class_list":["post-106875","post","type-post","status-publish","format-standard","has-post-thumbnail","category-entities","tag-som-biotech-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington&#039;s disease\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington&#039;s disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T14:19:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-22T11:48:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/10\/Adobe-Express-file-63.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease\",\"datePublished\":\"2025-10-21T14:19:31+00:00\",\"dateModified\":\"2025-10-22T11:48:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/\"},\"wordCount\":605,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Adobe-Express-file-63.jpg\",\"keywords\":[\"SOM Biotech\"],\"articleSection\":[\"ENTITIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/\",\"name\":\"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Adobe-Express-file-63.jpg\",\"datePublished\":\"2025-10-21T14:19:31+00:00\",\"dateModified\":\"2025-10-22T11:48:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington's disease\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Adobe-Express-file-63.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Adobe-Express-file-63.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease - Parc Cient\u00edfic de Barcelona","description":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington's disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/","og_locale":"en_US","og_type":"article","og_title":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease - Parc Cient\u00edfic de Barcelona","og_description":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington's disease","og_url":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2025-10-21T14:19:31+00:00","article_modified_time":"2025-10-22T11:48:51+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/10\/Adobe-Express-file-63.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease","datePublished":"2025-10-21T14:19:31+00:00","dateModified":"2025-10-22T11:48:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/"},"wordCount":605,"image":{"@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/10\/Adobe-Express-file-63.jpg","keywords":["SOM Biotech"],"articleSection":["ENTITIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/","url":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/","name":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/10\/Adobe-Express-file-63.jpg","datePublished":"2025-10-21T14:19:31+00:00","dateModified":"2025-10-22T11:48:51+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington's disease","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/10\/Adobe-Express-file-63.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/10\/Adobe-Express-file-63.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/la-fda-dona-llum-verda-a-som-biotech-per-iniciar-la-fase-3-de-som3355-un-nou-tractament-prometedor-per-a-la-malaltia-de-huntington\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"The FDA has approved SOM Biotech\u2019s Phase 3 study design for SOM3355, a potential drug for Huntington disease"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/106875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=106875"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/106875\/revisions"}],"predecessor-version":[{"id":106878,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/106875\/revisions\/106878"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/106869"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=106875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=106875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=106875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}